Online citations, reference lists, and bibliographies.
← Back to Search

Hepatitis A Vaccine Administration: Comparison Between Jet-injector And Needle Injection.

J. Williams, L. Fox-Leyva, C. Christensen, D. Fisher, E. Schlicting, M. Snowball, S. Negus, J. Mayers, R. Koller, R. Stout
Published 2000 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
INTRODUCTION Type A hepatitis virus (HAV) is a serious health problem throughout the world and can be spread via fecal-oral contact. Both immune globulin and an HAV vaccine provide protection, but the vaccine gives complete protection. Efficacy of methods of vaccination in relation to the formation of anti-HAV antibodies is unclear; thus, this study seeks to determine if significant differences exist between the syringe as compared to the jet injection technique. The purpose of this study was to compare in a randomized trial Biojet jet-injection system to a needle-syringe method. To determine if a significant difference between these two methods in seroconversion rates or geometric mean titers of anti HAV antibody occurs at day 15, 30, and 210 days after vaccination. METHOD Anti-HAV IgG(-) adult hospital employees were randomized to receive 1440 EL.U of hepatitis a vaccine (HAVRIX(R)) in 2 doses by either needle or jet-injector (Biojector(R)) system at month 0 and 6. HAV seroconversion titer results were measured by the Boehringer-Mannheim method. RESULTS/DISCUSSION A higher proportion of persons who received HAV vaccine via the Biojector(R) seroconverted with anti-HAV level >/=20 mIU at day 15, 30, and month 7 when compared with a needle injection.Side-effect profiles reported by participants in both methods were below those identified in current published and insert information, but the Biojector(R) had greater local reactivity in all categories when compared to the needle method.
This paper references
10.1016/0264-410X(93)90204-B
Preparation and immunogenicity of an inactivated hepatitis A vaccine.
V. Pellegrini (1993)
10.1007/BF01638256
[Mycobacterium ulcerans infection in man (Baruli-ulcer)].
G. Kieninger (1973)
10.1016/S0264-410X(97)00211-9
Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine.
H. Maiwald (1997)
10.1016/0264-410X(94)90303-4
Inadequate response to intradermal hepatitis A vaccine.
R. Brindle (1994)
10.1016/0264-410X(93)90291-5
Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A.
A. Delem (1993)
10.1016/S0264-410X(96)00173-9
Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group.
I. Parent du Châtelet (1997)
10.1007/BF01739313
Polyphasic type a hepatitis: Histological features
D. Villari (1993)
Van Damme A.
M. Haine (1986)
10.1016/0264-410X(88)90097-7
Laboratory markers for over-attenuation of mumps vaccine virus.
Boriskin YuS (1988)
10.1001/JAMA.1994.03510410040030
Protection against hepatitis A by an inactivated vaccine.
B. Innis (1994)
10.1016/S0264-410X(96)00242-3
Inactivated hepatitis A vaccine: long-term antibody persistence.
G. Wiedermann (1997)
10.1002/JMV.1890120207
Subcutaneous administration of inactivated hepatitis B vaccine by automatic jet injection
S. Lemon (1983)
10.1002/JMV.1890440427
Interruption of an outbreak of hepatitis A in two villages by vaccination
V. Prikazský (1994)
10.1093/clinchem/43.8.1494
Type A viral hepatitis: epidemiology, diagnosis, and prevention.
S. Lemon (1997)
10.1016/S0264-410X(96)00084-9
Two year old hepatitis A vaccine is as good as new.
E. Rajan (1996)
10.1016/S0264-410X(96)00196-X
Hepatitis B vaccine administration: comparison between jet-gun and syringe and needle.
C. Matheï (1997)
10.1016/0264-410X(95)00224-O
Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other "travellers" vaccines with the immune response.
U. Bienzle (1996)
10.1016/0140-6736(93)91274-P
Severe hepatitis A despite passive immunisation
R. Behrens (1993)



This paper is referenced by
Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection.
M. Gottlieb (2008)
Prime-boost immunization strategies against HIV-1
A. Bråve (2007)
10.1016/j.addr.2014.10.002
Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges.
Jose L. Tlaxca (2015)
10.22028/D291-23017
Methods and models for the investigation ofthe uptake of nanoparticles into hair follicles
A. S. Raber (2014)
10.1016/j.vaccine.2011.05.085
The influence of molecular adjuvants in the cutaneous response to antigen after topical vaccination.
Roy Himes (2011)
10.1016/B978-1-4557-0090-5.00063-X
Alternative vaccine delivery methods
B. Weniger (2013)
10.1089/VIM.2005.18.205
Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model.
Jun-ichi Imoto (2005)
Intradermal Delivery of Vaccines
(2009)
Exploration of parameters affecting jet injection using a high-speed X-ray imaging system
G. H. Park (2015)
10.1586/14760584.2014.883285
Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature
C. Herzog (2014)
10.1016/j.ijpharm.2011.07.002
Needle-free and microneedle drug delivery in children: a case for disease-modifying antirheumatic drugs (DMARDs).
U. Shah (2011)
10.1016/j.jconrel.2010.10.033
Separable arrowhead microneedles.
L. Y. Chu (2011)
10.1016/J.YMTHE.2006.01.013
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.
J. Nemunaitis (2006)
Development of a therapeutic vaccine against the hepatitis C virus
G. Ahlén (2007)
10.1016/S1046-2023(03)00138-5
Genetic immunization by jet injection of targeted pDNA-coated nanoparticles.
R. Mumper (2003)
10.1016/j.jconrel.2017.05.003
Delivery of immunoreactive antigen using a controllable needle‐free jet injector
Catherine Hogan (2017)
10.1016/B978-0-323-35761-6.00024-9
24 – Hepatitis A Vaccines
F. Averhoff (2018)
10.1208/s12249-019-1564-z
Stable Immune Response Induced by Intradermal DNA Vaccination by a Novel Needleless Pyro-Drive Jet Injector
Chinyang Chang (2019)
10.1016/j.cct.2014.11.014
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study.
Reinaldo de Menezes Martins (2015)
10.1016/j.jconrel.2010.09.018
Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
S. Bal (2010)
10.1016/j.vaccine.2018.04.015
Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use.
R. Link-Gelles (2018)
10.1016/B978-1-4160-3611-1.50065-9
Alternative vaccine delivery methods
B. Weniger (2008)
10.1016/j.vaccine.2014.01.086
Hepatitis A vaccination for post-exposure prophylaxis in persons aged 40 years and older.
N. Nelson (2014)
10.1007/82_2011_123
Delivery Systems for Intradermal Vaccination
Y. C. Kim (2012)
10.1586/17434440.3.5.565
Needle-free liquid jet injections: mechanisms and applications
Joy Baxter (2006)
10.4155/ppa.15.38
Recent advances in vaccine delivery.
A. S. Cordeiro (2016)
10.1016/S0264-410X(03)00250-0
Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults.
J. Williams (2003)
10.1517/17425247.2013.760542
Transcutaneous vaccines – current and emerging strategies
Sachiko Hirobe (2013)
10.1007/978-3-662-53273-7_30
Skin Vaccination Methods: Gene Gun, Jet Injector, Tattoo Vaccine, and Microneedle
Y. Kim (2017)
10.1016/j.vaccine.2011.11.020
Devices for intradermal vaccination.
E. E. Kis (2012)
Dissolving microneedles for cutaneous drug and vaccine delivery
Leonard Y. Chu (2009)
10.3233/JPI-2010-0269
Long-term immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years
K. Byrd (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar